sb 203580 has been researched along with gefitinib in 17 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 5,231 | 566 | 2,919 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (29.41) | 29.6817 |
| 2010's | 10 (58.82) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Atteridge, CE; Azimioara, MD; Benedetti, MG; Biggs, WH; Carter, TA; Ciceri, P; Edeen, PT; Fabian, MA; Floyd, M; Ford, JM; Galvin, M; Gerlach, JL; Grotzfeld, RM; Herrgard, S; Insko, DE; Insko, MA; Lai, AG; Lélias, JM; Lockhart, DJ; Mehta, SA; Milanov, ZV; Patel, HK; Treiber, DK; Velasco, AM; Wodicka, LM; Zarrinkar, PP | 1 |
| Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M | 1 |
| Atteridge, CE; Campbell, BT; Chan, KW; Ciceri, P; Davis, MI; Edeen, PT; Faraoni, R; Floyd, M; Gallant, P; Herrgard, S; Hunt, JP; Karaman, MW; Lockhart, DJ; Milanov, ZV; Morrison, MJ; Pallares, G; Patel, HK; Pritchard, S; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Hajduk, PJ; Johnson, EF; Kifle, L; Merta, PJ; Metz, JT; Soni, NB | 1 |
| Russu, WA; Shallal, HM | 1 |
| Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Al-Mazaideh, GM; Erdmann, F; Göllner, C; Rohe, A; Schmidt, M; Sippl, W; Wichapong, K | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Barouch-Bentov, R; Bekerman, E; Chaikuad, A; Chang, L; De Jonghe, S; Einav, S; Herdewijn, P; Heroven, C; Knapp, S; Kovackova, S; Neveu, G; Šála, M | 1 |
| Bharate, SB; Raghuvanshi, R | 1 |
| Caballero, E; García-Cárceles, J; Gil, C; Martínez, A | 1 |
| Chayama, K; Kuwahara, K; Miyata, H; Sasaki, T; Serikawa, M | 1 |
| Guo, J; Sheng, G; Warner, BW | 1 |
| Bollinger, N; Joslin, EJ; Lauffenburger, DA; Opresko, LK; Shankaran, H; Wiley, HS | 1 |
| Chen, SC; Chiou, SJ; Chuang, LY; Guh, JY; Hwang, CC; Ko, YM; Lin, TD | 1 |
| Chen, J; Li, JY; Shi, JY; Su, B; Tang, L; Yang, XJ; Zhang, J; Zhao, YM | 1 |
| Jeong, YJ; Kim, CH; Kim, DJ; Kim, JC; Lee, KB; Oh, SM; Park, JH | 1 |
1 review(s) available for sb 203580 and gefitinib
| Article | Year |
|---|---|
Kinase Inhibitors as Underexplored Antiviral Agents.
Topics: Animals; Antiviral Agents; Drug Repositioning; Humans; Protein Kinase Inhibitors; Virus Diseases; Viruses | 2022 |
16 other study(ies) available for sb 203580 and gefitinib
| Article | Year |
|---|---|
A small molecule-kinase interaction map for clinical kinase inhibitors.
Topics: Benzamides; Drug Design; Escherichia coli; Escherichia coli Proteins; Imatinib Mesylate; Microchemistry; Pharmaceutical Preparations; Piperazines; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Pyrimidines | 2005 |
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases | 2007 |
A quantitative analysis of kinase inhibitor selectivity.
Topics: Binding Sites; Enzyme Activation; Humans; Phosphotransferases; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Proteome; Quantitative Structure-Activity Relationship | 2008 |
Navigating the kinome.
Topics: Drug Design; Pharmacogenetics; Protein Kinases; Proteome; Systems Biology | 2011 |
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship | 2011 |
Comprehensive analysis of kinase inhibitor selectivity.
Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity | 2011 |
Evaluation of potential Myt1 kinase inhibitors by TR-FRET based binding assay.
Topics: Dose-Response Relationship, Drug; Fluorescence Resonance Energy Transfer; Glycolipids; Humans; Membrane Proteins; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Structure-Activity Relationship | 2013 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Selective Inhibitors of Cyclin G Associated Kinase (GAK) as Anti-Hepatitis C Agents.
Topics: Antiviral Agents; Cell Line; Crystallography, X-Ray; Hepacivirus; Hepatitis C; Humans; Intracellular Signaling Peptides and Proteins; Models, Molecular; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyridines; Thiazoles; Virus Internalization | 2015 |
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |
The effects of ZD1839 (Iressa), a highly selective EGFR tyrosine kinase inhibitor, as a radiosensitiser in bile duct carcinoma cell lines.
Topics: Anthracenes; Bile Duct Neoplasms; Butadienes; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromones; Clone Cells; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Imidazoles; JNK Mitogen-Activated Protein Kinases; Mitogen-Activated Protein Kinases; Morpholines; Nitriles; Oncogene Protein v-akt; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Quinazolines; Radiation-Sensitizing Agents | 2006 |
Epidermal growth factor receptor signaling modulates apoptosis via p38alpha MAPK-dependent activation of Bax in intestinal epithelial cells.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Cell Line; Dose-Response Relationship, Drug; Enterocytes; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Ileum; Imidazoles; Mitochondria; Mitogen-Activated Protein Kinase 14; Phosphorylation; Protein Kinase Inhibitors; Protein Transport; Pyridines; Quinazolines; Rats; RNA Interference; RNA, Small Interfering; Signal Transduction; Time Factors; Tyrphostins | 2007 |
Structure of the EGF receptor transactivation circuit integrates multiple signals with cell context.
Topics: Cell Line; Dose-Response Relationship, Drug; Epithelial Cells; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Gefitinib; Gene Regulatory Networks; Hepatocyte Growth Factor; Humans; Imidazoles; Ligands; Lysophospholipids; Mammary Glands, Human; Phosphorylation; Pyridines; Quinazolines; Signal Transduction; Transcriptional Activation; Transforming Growth Factor alpha | 2010 |
Gefitinib attenuates transforming growth factor-β1-activated mitogen-activated protein kinases and mitogenesis in NRK-49F cells.
Topics: Animals; Benzamides; Cell Line; Collagen; Cyclin D1; Dioxoles; Enzyme Inhibitors; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Fibroblasts; Flavonoids; Gefitinib; Imidazoles; Kidney; MAP Kinase Signaling System; Mice; Mitosis; Models, Biological; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyridines; Quinazolines; Rats; Receptors, Transforming Growth Factor beta; Smad Proteins; Transforming Growth Factor beta1; Translational Research, Biomedical | 2011 |
[Small molecule inhibitor SB203580 enhances the antitumor effect of gefitinib in PC-9 and A549 lung cancer cell lines].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme Inhibitors; Gefitinib; Humans; Imidazoles; Lung Neoplasms; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyridines; Quinazolines; Signal Transduction | 2013 |
RIP2/RICK-dependent cytokine production upon Yersinia enterocolitica infection in macrophages with TLR4 deficiency.
Topics: Animals; Enzyme Inhibitors; Gefitinib; Imidazoles; Interleukin-10; Interleukin-6; Macrophages; Mice; Mice, Inbred C57BL; Mice, Knockout; Nod1 Signaling Adaptor Protein; Nod2 Signaling Adaptor Protein; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinazolines; Receptor-Interacting Protein Serine-Threonine Kinase 2; Receptor-Interacting Protein Serine-Threonine Kinases; Signal Transduction; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha; Yersinia enterocolitica; Yersinia Infections | 2013 |